Clinical

Dataset Information

0

Optimal Anti-EGFR Treatment of mCRC Patients With Low-Frequency RAS Mutation


ABSTRACT: The present hypothesis is that anti-EGFR agents are active in tumors with low-level RAS mutation when the majority of tumor cells is still sensitive. While response rate may be high and may reflect sensitivity to anti-EGFR agents, PFS is anticipated to be shorter than in RAS wild-type patients due to the faster development of resistance when sensitive cells are eradicated and when the RAS-mutant anti-EGFR resistant clones become predominant. The characteristics of low-level RAS mutant tumors would be: * Objective response rate (ORR) high (reflecting the sensitive clone) * Progression-free survival (PFS) short (reflecting the more rapid outgrowth of RAS mutant clones)

DISEASE(S): Neoplasms, Second Primary,Treatment Related Cancer,Colorectal Cancer

PROVIDER: 2312021 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

2019-01-23 | GSE102995 | GEO
2020-05-27 | PXD014755 | Pride
2021-04-08 | GSE171650 | GEO
2024-11-08 | GSE235417 | GEO
2023-07-05 | GSE235919 | GEO
2023-07-05 | GSE235917 | GEO
2018-08-29 | GSE113146 | GEO
2023-11-20 | PXD047029 | Pride
2023-08-14 | PXD043799 | Pride
2012-01-11 | GSE29415 | GEO